New studies suggest GLP 1 medications could reduce cancer risk, spread and death rates

Weight loss drugs already celebrated for helping millions shed excess pounds may soon earn recognition for something even more significant.

New research suggests these medications could play an important role in reducing the risk of developing cancer, preventing disease progression and even lowering death rates among some patients.

The findings were unveiled at the annual meeting of the American Society of Clinical Oncology in Chicago, where researchers presented a series of studies examining the impact of GLP 1 medications on cancer outcomes.

The results have generated considerable excitement within the medical community.

GLP 1 medications were originally developed to help manage type 2 diabetes. In recent years, they have become widely known for their effectiveness in treating obesity and supporting long term weight loss.

Now researchers believe the drugs may offer additional benefits that extend far beyond weight management.

One of the largest studies analysed more than 110,000 women aged between 45 and 80. Researchers found that women taking GLP 1 medications were 30 percent less likely to develop breast cancer compared with women who were not using the drugs.

The study was led by Dr Elizabeth McDonald, who said the findings add to growing evidence that these medications deserve further investigation as possible cancer prevention tools.

While the research does not prove a direct cause and effect relationship, it strengthens the case for larger studies exploring how GLP 1 medications influence cancer development.

A second study involving 27,000 breast cancer patients produced similarly striking results.

Researchers found that adding GLP 1 medications to standard breast cancer treatment was associated with a 30 percent reduction in the risk of death from the disease.

Meanwhile, a third investigation examined patients with breast, lung, bowel and liver cancers.

That research found that people taking weight loss drugs were between 38 percent and 50 percent less likely to develop advanced stage four disease compared with patients who were not using the medications.

Scientists believe several biological mechanisms may help explain these findings.

Maintaining a healthy weight has long been recognised as an important factor in reducing cancer risk, particularly for breast cancer. Obesity is known to increase the likelihood of developing several forms of the disease.

However, researchers suspect the benefits of GLP 1 drugs may go beyond weight reduction alone.

The medications are known to reduce inflammation throughout the body. Chronic low grade inflammation has been linked to cancer development for many years. Scientists also believe the drugs may influence metabolic and cellular pathways involved in tumour growth.

According to Dr McDonald, multiple effects may work together to reduce the likelihood of cancer developing or progressing.

Experts not involved in the studies have also expressed interest in the findings.

Dr Marcin Chwistek noted that GLP 1 receptor agonists have long demonstrated anti inflammatory and immune related effects beyond blood sugar control.

Meanwhile, Dr Eleonora Teplinsky said there is now enough evidence to suggest these medications influence either cancer risk or recurrence, although researchers have not yet fully identified the exact reasons.

She emphasised that more clinical trials are needed before firm conclusions can be reached.

Researchers caution that the studies presented were observational and should not be viewed as definitive proof that weight loss drugs directly prevent cancer.

Even so, the consistency of the findings across multiple studies has attracted significant attention.

Interest in this area is growing rapidly as scientists explore whether a medication originally designed for diabetes and obesity could become part of a future cancer prevention and treatment strategy.

For now, experts agree on one point. The results are promising and could mark the beginning of a major new chapter in cancer research.